Keio University To Research iPS Cells Of Alzheimer's Disease Patients
This article was originally published in PharmAsia News
Keio University announced May 27 that it will start producing induced pluripotent stem cells from skin cells provided by patients with nervous system diseases such as Alzheimer's. The university will conduct research on the iPS cells in hopes of discovering the causes for the diseases and developing new therapeutic drugs. The team is also considering providing the iPS cells to other research facilities and companies to aid their new drug discovery effort. Besides AD, 25 other diseases are included in the research, such as Parkinson's disease, amyotrophic lateral sclerosis and retinal degeneration. (Click here for more - Japanese language
You may also be interested in...
TOKYO - Bayer Schering Pharma signed a licensing agreement for worldwide development and distribution of diagnostic radioactive tracers made from compounds developed by Nagasaki University to detect Alzheimer's disease, Morio Nakayama, head of research, told PharmAsia News Sept. 17
Drug companies involved in Alzheimer's disease research are a little fed up with FDA. Some, like Wyeth, believe the agency should put Alzheimer's research higher up on its priority list and allow the use of surrogate endpoints for clinical trials. But FDA says that no validated surrogate exists for Alzheimer's, and until it has hard data from products in development, it is loath to recommend one. A recent reorganization of the agency's neurology group may provide an opening to press home those arguments.
The use of virtual, real-time and at-home testing to provide clinical trials data has been steadily gaining the interest of the health care industry. COVID-19 has put this opportunity into sharper focus, says CNS trials technology developer Cambridge Cognition, which is now adding a voice option to its portfolio.